Symptom relief, prognostic factors, and outcome in patients receiving urgent radiation therapy for superior vena cava syndrome

PurposeSuperior vena cava syndrome (SVCS) often results from external vessel compression due to tumor growth. Urgent symptom-guided radiotherapy (RT) remains a major treatment approach in histologically proven, rapidly progressive disease. Despite several publications, recent data concerning symptom...

Full description

Saved in:
Bibliographic Details
Published in:Strahlentherapie und Onkologie 2022-12, Vol.198 (12), p.1072-1081
Main Authors: Guhlich, Manuel, Maag, Teresa Esther, Dröge, Leif Hendrik, El Shafie, Rami A, Hille, Andrea, Donath, Sandra, Schirmer, Markus Anton, Knaus, Olga, Nauck, Friedemann, Overbeck, Tobias Raphael, Hinterthaner, Marc, Körber, Wolfgang, Andreas, Stefan, Rittmeyer, Achim, Leu, Martin, Rieken, Stefan
Format: Article
Language:English
Subjects:
Chemotherapy
Evaluation
Health care facilities
Health services
Medical prognosis
Radiation therapy
Rank tests
Regression analysis
Survival
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:PurposeSuperior vena cava syndrome (SVCS) often results from external vessel compression due to tumor growth. Urgent symptom-guided radiotherapy (RT) remains a major treatment approach in histologically proven, rapidly progressive disease. Despite several publications, recent data concerning symptom relief and oncological outcome as well as potential confounders in treatment response are still scarce.MethodsWe performed a retrospective single-center analysis of patients receiving urgent RT between 2000 and 2021 at the University Medical Center Göttingen. Symptom relief was evaluated by CTCAE score during the RT course. Effects of variables on symptom relief were assessed by logistic regression. The impact of parameters on overall survival (OS) was evaluated using Kaplan–Meier plot along with the log-rank test and by Cox regression analyses. Statistically significant (p-value  2 years). Applied RT dose > 39 Gy, clinical target volume (CTV) size
ISSN:0179-7158
1439-099X
DOI:10.1007/s00066-022-01952-z